Hyper Lab Blog

We introduce a case study on utilizing Hyper Screening to develop a MARK4 inhibitor drug. This article covers the process from identifying initial hit compounds to analyzing experimental results.

AI Drug Discovery: From 5 Years to Just 3 Months—Discovering a 100nM Active Compound with Hyper Lab

Oncology, immunology, and metabolic diseases dominated the top 50 FDA-approved drugs in 2024, with innovative treatments like Lazertinib and diverse drug types.

We interviewed Prof. Jan Korabecny and Barbora Svobodova, drug discovery researchers at the Biomedical Research Center at the Czech University Hospital, about their experience with Hyper Lab.

Originally developed 30 years ago, the traditional MSA technique has dramatically enhanced AlphaFold’s protein structure prediction accuracy, bringing it back into the spotlight after years of relative obscurity.

Cobenfy is an FDA-approved oral schizophrenia treatment targeting muscarinic rather than dopamine receptors. Its rapid symptom improvement and fewer side effects hint at a paradigm shift, making upcoming clinical findings highly anticipated.

Did you know that molecular docking, a key tool in drug discovery, can yield vastly different results depending on how you configure settings like thoroughness, scoring functions, and flexible residues?

Ultra-large compound libraries leverage DEL technology and AI to increase the efficiency of drug discovery, expanding chemical diversity and the potential for hit discovery.

Sunghan Bae from the HITS AI research team won the 2nd AI Drug Discovery Competition, utilizing the MolClr model and HyperLab's binding affinity predictions to overcome data shortages and imbalances.

Seladelpar, a treatment for Primary Biliary Cholangitis, has received FDA accelerated approval. This rare autoimmune disease, mainly affecting middle-aged women, is now addressed by seladelpar’s high selectivity and fewer side effects.